OINDPnews


Aptar Pharma banner

Medical

Positive results for Lightlake intranasal naloxone study

According to Lightlake Therapeutics, initial results from a two-week PK study of intranasal naloxone for the treatment of opioid overdose shows that the nasal spray gets naloxone into the bloodstream as fast as injection. The study, which began September 23, 2013, was conducted in conjunction with the National Institute on Drug Abuse (NIDA). Lightlake CFO Kevin … [Read more...] about Positive results for Lightlake intranasal naloxone study

Study finds out-of-hospital intranasal fentanyl safe and effective

A study by Danish researchers published online November 25, 2013 by the Annals of Emergency Medicine found that intranasal fentanyl administered by ambulance workers prior to delivery of patients to the hospital appeared to be safe and effective. The study involved over 900 patients, including adults and children older than 8, who were in severe pain. The patients … [Read more...] about Study finds out-of-hospital intranasal fentanyl safe and effective

Cornerstone launches Bethkis tobramycin inhalation solution

Cornerstone Therapeutics has launched Bethkis tobramycin inhalation solution for the treatment of cystic fibrosis patients with P. aeruginosa infections in the US, the company said. According to Cornerstone, one dose of Bethkis contains 300 mg of tobramycin in 4 mls of solution and can be delivered in about 15 minutes using a PARI LC Plus nebulizer. The company … [Read more...] about Cornerstone launches Bethkis tobramycin inhalation solution

Milestone initiates Phase 1 trial of intranasal calcium channel antagonist

Canadian cardiovascular drug development company Milestone Pharmaceuticals has initiated a Phase 1 clinical trial of its lead product, MSP-2017 intranasal short-acting calcium channel antagonist for the treatment of paroxysmal supraventricular tachycardia (PSVT), the company announced. The randomized, double-blind, placebo-controlled crossover study will take place in … [Read more...] about Milestone initiates Phase 1 trial of intranasal calcium channel antagonist

Puget Technologies says it will develop intranasal cannabinoids

Florida-based Puget Technologies has announced that its subsidiary Cannabis Biotech has initiated a research project to develop an intranasal formulation of cannabinoids, saying that the "project is targeted towards those who desire the benefits of medical marijuana but do not want the harmful effects or stigma of smoking it." The company said that the project will be … [Read more...] about Puget Technologies says it will develop intranasal cannabinoids

Positive results in artificial pancreas plus inhaled insulin study

Diabetes research organization JDRF, along with Sansum Diabetes Research Institute, and the College of Engineering at University of California, Santa Barbara (UCSB) have announced positive results from a trial of an artificial pancreas used in conjunction with inhaled insulin taken at mealtimes. In 2010, MannKind Corporation announced that it would provide Afrezza … [Read more...] about Positive results in artificial pancreas plus inhaled insulin study